ZW25

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

ZW25 (also known as Zanidatamab) is an investigational medication being studied for certain types of cancers, including colorectal cancer (CRC). It is currently in Phase 2 clinical trials. The trials are specifically looking at patients whose tumors express HER2 (Human Epidermal growth factor Receptor 2). ZW25 is being tested in combination with standard chemotherapy regimens (like XELOX, FP, mFOLFOX6, or CisGem) to see if it improves treatment outcomes compared to chemotherapy alone. The goal of the trials is to assess the safety and effectiveness of ZW25 in this setting. It is not yet approved for use in CRC or any other cancer.

Mechanism of Action

ZW25 is designed to target HER2, a protein found on the surface of some cancer cells. HER2 helps cancer cells grow and spread. ZW25 is a type of antibody-drug conjugate (ADC). This means it combines an antibody that specifically binds to HER2 with a chemotherapy drug. The antibody delivers the chemotherapy drug directly to the cancer cells that have HER2, potentially causing more targeted damage with fewer effects on normal cells. The specific chemotherapy drug attached to the antibody is not specified in the provided data.

Side Effects

As ZW25 is an investigational drug Its side effect profile is still being evaluated in clinical trials. The most informative trial (NCT03929666) is assessing the safety and tolerability of ZW25 in combination with chemotherapy. Common side effects associated with chemotherapy regimens used in the trial (like XELOX FP MFOLFOX6 CisGem) can include nausea Vomiting Diarrhea Fatigue Hair loss Low blood counts And mouth sores. Side effects specific to ZW25 itself Or unique side effects from the combination Are being carefully monitored in the trials. More detailed information on side effects will become available as the trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03929666 Phase 2
Completed
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
United States, Canada, Chile, South Korea

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.